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Background: Antipsychotics are frequently and increasingly prescribed to treat the behavioural symptoms
associated with dementia despite their modest efficacy. Evidence regarding the potential adverse events of
antipsychotics is limited and little is known about the longer-term safety of these medicines in the elderly. The aim
of this review was to determine the impact of the choice of observational study design and methods used to
control for confounding on the measurement of antipsychotic risks in elderly patients.
Methods: We searched PUBMED and the Cochrane controlled trials register for double-blind randomised controlled
trials (RCTs), meta-analyses and published observational studies of antipsychotics.
Results: Forty four studies were identified for the endpoints; death, cerebrovascular events, hip fracture and
pneumonia. RCTs found a 20% to 30% increased risk of death, or an absolute increase of 1extra death per 100
patients with atypical antipsychotics compared to non-use. Cohort and instrumental variable analyses estimated
between 2 to 7 extra deaths per 100 patients with conventional compared to atypical antipsychotics. RCTs found a
2 to 3 times increased risk of all cerebrovascular events with atypical antipsychotics compared to placebo and no
association with serious stroke that required hospitalisation. Observational studies using cohort and self-controlled
case-series designs reported similar results; no association where the endpoint was stroke causing hospitalisation
and a doubling of risk when minor stroke was included. No RCTs were available for the outcome of hip fracture or
pneumonia. Observational studies reported a 20% to 40% increased risk of hip fracture with both antipsychotic
classes compared to non-use. The risk of pneumonia was a 2 to 3 times greater with both classes compared to
non-use while a self-controlled case-series study estimated a 60% increased risk. Conventional antipsychotics were
associated with a 50% greater hip fracture risk than atypical antipsychotics, while the risk of pneumonia was similar
between the classes.
Conclusions: Choice of observational study design is critical in studying the adverse effects of antispychotics.
Cohort and instrumental variable analyses gave more consistent results to clinical studies for mortality outcomes as
have self-controlled case-series for the risk of cerebrovascular events and stroke. Observational evidence has
highlighted the potential for antipsychotics to be associated with serious adverse events that were not reported in
RCTs including hip fracture and pneumonia. Good quality observational studies are required, that employ
appropriate study designs that are robust towards unmeasured confounding, to confirm the potential excess risk of
hip fracture and pneumonia with antipsychotics.
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Antipsychotics are frequently, and increasingly, pre-
scribed to treat the behavioural symptoms associated
with dementia despite their modest efficacy and poten-
tial for serious side effects [1,2]. A Cochrane review [2]
failed to find any evidence of benefit with haloperidol
treatment in patients with agitated dementia and recom-
mended that it should not be used routinely. Another
Cochrane review [1] found that atypical antipsychotics
may help to improve symptoms of dementia such as ag-
gression, psychosis and agitation,[3-7] however, improve-
ments were often limited to patients with more severe
dementia [5]. Large head to head randomised trials of
atypical and conventional antipsychotics have not been
performed in the elderly, however, one post-hoc analysis
of a small experimental study [8] found that risperidone
may be more effective in reducing aggressiveness than
haloperidol.
Side effects are common with both classes of antipsy-
chotics and include; extra-pyramidal symptoms [3-7]
and somnolence [4-6]. These effects may be less fre-
quent [9] and less severe [8] with risperidone compared
to haloperidol, but only at lower doses of the medicines
[9]. Experimental evidence regarding the more serious
adverse events of antipsychotics is limited to atypical
antipsychotics and little is known about the safety of
conventional antipsychotics in the elderly. Furthermore,
most randomised controlled trials have limited follow-
up of up to 12 weeks [1] and the safety of both anti-
psychotic classes with long-term treatment remains
unclear.
Post marketing observational studies of antipsychotics
have identified many safety issues associated with anti-
psychotics, however, study results vary and conclusions
are inconsistent.
Previous reviews of observational studies of antispy-
chotics have focused on the clinical safety of conven-
tional and atypical antipsychotics [10-13]. The aim of
this review was to synthesise the current evidence from
observational studies, regarding the serious adverse
events of antipsychotics in elderly patients and to deter-
mine the impact of the observational study design uti-
lised and the technique employed to control for
confounding on study results.
A review of available meta-analyses of randomised
controlled trial evidence was performed for comparison
purposes. The endpoints of interest were death, cerebro-
vascular events, hip fracture and pneumonia.
Methods
This review was performed according to the Quality of
Reporting of Meta-analyses (PRISMA http://www.
prisma-statement.org/) guidelines (see online Additional
File 1 PRISMA 2009 checklist).We searched the PUBMED database and the Cochrane
controlled trials register for all English-language articles
published up to December 2010. We also conducted a
manual search of bibliographies for other relevant arti-
cles. We included double-blind randomised controlled
trials (RCTs), meta-analyses and published observational
studies that evaluated adverse events of either conven-
tional or atypical antipsychotic medications in elderly
populations. All studies were included if they reported at
least one of the adverse events of interest; death, cere-
brovascular events, hip fracture or pneumonia. Studies
specifically investigating the use of antipsychotics in
schizophrenic patients were not included. Individual
RCTs contributing to meta-analysis were not included in
this review to avoid double counting of studies. In
PUBMED we combined the results of 2 search domains:
Dementia (MESH terms Dementia OR Dementia, Vascu-
lar NOT Schizophrenia), and drug therapy (Anti-
psychotic Agents) with each of the following searches
for the outcomes of interest; death (Death OR Death,
Sudden, Cardiac OR Death, Sudden OR Mortality), cere-
brovascular events (Stroke), hip fracture (Hip Fractures)
and pneumonia (Pneumonia OR Pneumonia, Bacterial
OR Pneumonia, Aspiration). Author 1 (NP) was respon-
sible for the retrieval and review of studies to be
included in the final review. Author 2 (ER) provided in-
dependent assessment of studies when required.
We identified 106 articles, 7 of which were duplicates.
Of the 99 unique records, 33 articles were excluded
based upon review of the title and abstract. We reviewed
66 full text articles, of which 22 were excluded (Figure 1).
Articles were excluded if they were editorials, letters, did
not contain original data or outcome data of interest or
were commentaries on already included published data.
We included observational studies that employed ei-
ther a case–control design, a cohort design or a self-
controlled case-series design. Studies that also used an
instrumental variable analysis in addition to the standard
cohort analysis were also included. The use of instru-
mental variables has been suggested as a possible alter-
native to conventional analyses when there is concern
about the effect of unmeasured confounding [14,15]. In-
strumental variable (IV) analysis attempts to mimic the
process of randomisation in an RCT by exploiting the
existence of another variable (the instrument) which can
be measured in the available data, which is highly corre-
lated with the probability of exposure but unrelated to
the outcome of interest except through its association
with treatment [16]. The instrument is similar to ran-
dom arm assignment in that it should distribute both
measured and unmeasured patient characteristics evenly
between exposure groups resulting in an estimate less
affected by confounding. The self-controlled case-series
design compares the risk of adverse events in periods of
Records excluded 
(n = 33)
Full-text articles excluded (n = 22)
Reasons: 
Editorial/Letter/health alert (n=10)
Not original Data (n=3)
Not target population (n=1)
No relevant outcome Data (n=5)
Not required study design (n=2)
Abstract only (n=1)
All articles identified through 
database searching, additional 
searches of related articles and 
citations 
(n = 106)




Full-text articles assessed 
for eligibility 
(n = 66)
Studies included in 
qualitative synthesis 
(n = 44)
Figure 1 Flow diagram of the selected studies.
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person. This design attempts to limit the effects of major
unmeasured confounders as the within-person study de-
sign controls implicitly for confounders that do not vary
over time [17].
The final identified studies were grouped by outcome
type and categorised according to the primary study
medication comparison. Studies were rated according to
a hierarchy of evidence of study designs [18] with meta
analyses considered as the highest level of evidence, ob-
servational studies were considered as lower quality.
Data were extracted including the study population,
study size, study design, propensity for bias, procedures
employed to minimise bias, a rating of study quality,
duration of follow-up, outcome rate in the reference
group, effect estimate (either rate ratio, odds ratio, haz-
ard ratio or risk difference depending on the study de-
sign utilised) and appropriate 95% confidence intervals.
The propensity for bias was assigned as ‘Low’ for RCTs
and ‘Moderate’ for observational studies. Study quality
was assigned as ‘High’ for RCTs. Observational studies
were assigned a ‘Moderate’ quality rating if specific
methods were employed to minimise bias otherwisestudies were assigned a ‘Low’ quality if they made only
minimal efforts to control for potential bias. Study
designs such as the self-controlled case-series or instru-
mental variable analysis are not formally recognised in
the hierarchy of evidence, however, we have considered
these studies as they attempt to account for the common
problem of unmeasured confounding in observational
studies. The probable place of instrumental variable ana-
lysis in the hierarchy is either equivalent to or better
than cohort studies. The place of the self-controlled
case-series is as yet unclear.
In this review we specifically aimed to determine the
extent to which the study design employed and the
methods utilised to control for confounding, impacted
on study results. Thus it was considered inappropriate
to proceed with a formal meta-analysis due to the likely
heterogeneity of studies.
Results
This review included 44 studies, 16 evaluated the risk of
death, 18 evaluated cerebrovascular events, 8 evaluated
the risk of hip fracture and 6 evaluated the risk of pneu-
monia associated with antipsychotic prescribing. Details
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in Table 1 for death outcomes, Table 2 for cerebrovasu-
lar events, Table 3 for hip fracture and Table 4 for
pneumonia.
Risk of death associated with antipsychotic medicines
Meta-analysis and RCT evidence: studies that compared
antipsychotic treatment to placebo
Meta-analyses of risperidone compared to placebo
showed a non-significant 20% to 30% increased relative
risk of death with short-term treatment (<12 weeks)
[5,19,20]. One additional RCT found a 42% increased
relative risk of death with atypical antipsychotics with
extended duration of treatment [21]. Only one RCT was
located that measured the risk of death associated with
conventional antipsychotics compared to placebo [8].
This study, limited to 12 weeks duration, found a non-
significant 68% increased relative risk of death with halo-
peridol [8], however, this may be due to insufficient
statistical power as the number of patients in this study
was small. No RCT evidence was available comparing
the risk of death between the classes.
Observational evidence: studies that compared
antipsychotic treatment to non-use
Observational cohort study evidence for atypical antipsy-
chotics compared to non-use [22] was consistent with the
longer duration RCT results [21] while a case–control
study gave a much higher estimate [23]. Three observa-
tional studies found that conventional antipsychotics were
associated with an increased risk of death compared to
non-use [23,25,26] while one [24] case–control study
found no difference in risk (Table 1).
Observational evidence: studies that compared
conventional and atypical antipsychotic treatment
The majority of observational studies comparing the risk
of death between the classes were performed using a co-
hort study design. Conventional antipsychotics were
consistently associated with a 20-40% relative increased
risk of death when compared to atypical antipsychotics
[22,26-29,31,32,56]. Absolute risks, however, varied be-
tween studies according to the method employed to
control for confounding. Conventional statistical meth-
ods adjusting for measured covariates suggested an
increased risk over 6 months of between 2 and 3 deaths
per 100 patients treated with conventional compared to
atypical antipsychotics [22,27,56] while those that used
an instrumental variable analysis, to adjust for unmeas-
ured confounding, found an increased risk of between 4
and 7 deaths per 100 patients treated over 6 months
[28,29] and up to 10 deaths per 100 over 12 months
[31]. Only one observational cohort study [26] and onecase–control study [23] found no significant difference
between the classes.Risk of cerebrovascular events associated with
antipsychotic medicines
Meta-analysis and RCT evidence: studies that compared
antipsychotic treatment to placebo
Five meta-analyses reported a significantly increased risk
of cerebrovascular events with atypical antipsychotics
compared to placebo [1,4-6,32] (Table 2). When the out-
come was limited to cerebrovascular events requiring
hospitalisation no increased risk was observed [4,32]. No
RCT evidence was located for the risk of cerebrovascular
events with conventional antipsychotics or for the com-
parison between classes.Observational evidence: studies that compared
antipsychotic treatment to non-use
Observational cohort studies found similar results to the
meta-analyses of atypical antipsychotics compared to
placebo. Of the two cohort studies, one study, that
included all diagnoses of stroke from general practi-
tioners’ medical records, found a significantly increased
risk [33], while the other, investigating the more serious
outcome definition of hospitalization for stroke, found
no association with atypical antipsychotics compared to
non-use [34]. Two case–control studies failed to find
any association between atypical antipsychotics and
cerebrovascular events compared to non-use [35,36].
Two studies using a self-controlled case-series design, to
adjust for unmeasured confounding, also found similar
results to the RCTs when similar definitions of cerebro-
vascular events were considered. One study found an
increased risk of stroke as diagnosed through general
practitioners’ medical records for up to 70 days after ini-
tiation of atypical antipsychotics [37] while the other
found no increased risk of hospitalization for stroke after
initiation of atypical antipsychotics [38].
The strongest available evidence for the risk of cere-
brovascular events with conventional antipsychotics was
from observational cohort studies. One study found a
significantly increased risk of stroke as diagnosed in gen-
eral practitioners’ medical records [33] while the other
found no increased risk of hospital admissions for cere-
brovascular events [34] (Table 2). Two case–control
studies failed to find any association between conven-
tional antipsychotics and cerebrovascular events [35,36].
One self-controlled case-series study found an increased
risk of stroke, as diagnosed in GPs’ medical records, with
conventional antipsychotic initiation compared to non-
use which persisted up to 140 days after treatment initi-
ation [37]. Another self-controlled case-series study
found that the risk of hospitalization for stroke was
Table 1 Studies on the risk of death associated with antipsychotic medicines








LEVEL I Evidence: Meta-Analyses
Studies that compared atypical antipsychotic (ATYP) treatment to placebo (PLA)
Katz [5] 895 Institutionalised dementia
patients (age>=55)
Death Low/High Yes 12 weeks 1.8% HR(RISP v PLA); 1.26 95% CI; 0.53-2.99
Schneider [19] 5,204 Dementia patients
(age>55)
Death Low/High Yes 6-26 weeks 2.3% OR(ATYP v PLA); 1.54 95% CI; 1.06-2.23
RD(ATYP - PLA); 0.01 95% CI; 0.004-0.02
2.8% OR(RISP v PLA); 1.30 95%CI; 0.76-2.23
Haupt [20] 1,721 Alzheimers Patients
(mean age 82.3)
Death Low/High Yes 4-12 weeks 3.1% RR(RISP v PLA); 1.21 95% CI; 0.71-2.06
LEVEL II Evidence: Randomised Controlled Trial
Studies that compared atypical antipsychotic (ATYP) treatment to placebo (PLA)
Ballard [21] 165 Institutionalised dementia
patients (mean age 85)
Death Low/High Yes 12 months 33% HR(RISP v PLA); 0.58 95% CI; 0.36-0.92
Studies that compared conventional antipsychotic (C) treatment to placebo (PLA)
DeDeyn [8] 344 Dementia patients (mean
age 81 placebo, 82 haloperidol)
Death Low/High Yes 12 weeks 3.8% OR(HAL v PLA); 1.68 95% CI; 0.72-3.92 [19]
LEVEL III Evidence: Observational Studies
Studies that compared atypical antipsychotic (ATYP) treatment to non-use (NU)
COHORT STUDIES
Gill [22] 9,100 matched pairs,
Non-institutionalised dementia
patients in a universal health






180 days 8.0% HR(ATYP v NU);1.32 95% CI; 1.12-1.54
RD(ATYP - NU); 1.1 per 100 95% CI; 0.1-2.1
Gill [22] 4,036 matched pairs, Institutionalised
dementia patients in a universal






180 days 15.1% HR(ATYP v NU);1.23 95% CI; 1.05-1.45
RD(ATYP - NU); 1.5 per 100 95% CI; -0.5-3.4
CASE-CONTROL STUDIES
Trifiro [23] 398 cases, 4,023 controls, dementia








9 years NA OR(ATYP v NU); 2.2 95% CI; 1.2-3.9






2 years 49.6% HR(ATYP v NU);0.49 95% CI; 0.24-0.99
Studies that compared conventional antipsychotic (CONV) treatment to non-use (NU)
COHORT STUDIES
Ray [25] 1,282,995 Non-institutionalised
dementia, medicaid-enrolled








1 year 11.3/10000 PY Moderate Dose >100mg: RR(CONV v NU);
2.39 95% CI; 1.77-3.22 Low Dose <100mg:




















Table 1 Studies on the risk of death associated with antipsychotic medicines (Continued)
Kales [26] 10,615 Veterans enrolled in
VA Serious Mental Illness Treatment
Research and Evaluation Centre,







1 year 25.2% RR(NU v CONV); 0.66 95% CI; 0.53-0.82
CASE-CONTROL STUDIES
Trifiro [23] 398 cases, 4,023 controls, dementia








9 years NA OR(CONV v NU); 1.8 95% CI; 1.4-2.3






2 years 49.6% HR(CONV v NU); 0.68 95% CI; 0.46-1.03
Studies that compared conventional antipsychotic (CONV) and atypical antipsychotic (ATYP) treatment
COHORT STUDIES







180 days 10.7% HR(CONV v ATYP); 1.23 95% CI; 1.00-1.50
RD(CONV - ATYP); 2.6 per 10095% CI;
0.5-4.5







180 days 17.8% HR(CONV v ATYP); 1.27 95% CI; 1.09-1.48
RD(CONV - ATYP); 2.2 per 100 95%
CI; 0.0-4.4
Hollis [27] 16,634 Australian Department






2 years 246 per
1000
RR (HALO v OLA); 2.26 95% CI; 2.08-2.47
RR (CHL v OLA); 1.39 95% CI; 1.15-1.67
Hollis [27] 6,602 Institutionalised Australian






2 years 291 per
1000
RR (HALO v OLA); 1.67 95% CI; 1.50-1.84
RR (CHL v OLA); 1.75 95% CI; 1.31-2.34
Kales [26] 10,615 Veterans enrolled in












1 year 25.2% Covariate adjusted RR(ATYP v CONV);
0.93 95% CI; 0.75-1.16









180 days 9.6% Covariate adjusted HR(CONV v ATYP);
1.32 95% CI; 1.23-1.42 PS adjusted
HR(CONV v ATYP); 1.39 95% CI; 1.30-1.49
IV RD(CONV – ATYP); 4.2 per 100,
95% CI; 1.2-7.3










180 days 14.6% Covariate adjusted HR(CONV v ATYP);
1.37 95% CI; 1.27-1.49 Propensity score
adjusted adjusted HR(CONV v ATYP);
1.37 95% CI; 1.27-1.49 IV RD(CONV - ATYP);
7.3 per 100 95% CI; 2.0-12.6










HR(CONV v ATYP); 1.26 95% CI; 1.13-1.42
HR (HALO v RISP); 1.31 95% CI; 1.13–1.53




















Table 1 Studies on the risk of death associated with antipsychotic medicines (Continued)
analysis, subgroup
analysis)
1.00–1.38 HR(Other Conventional v RISP);
1.32 95% CI; 0.99–1.80










1 year 37.4% Covariate adjusted RD(CONV v ATYP); 8.5
95% CI; 6.2-10.7 Propensity score
adjusted RD(CONV v ATYP); 9.1 95%
CI; 6.9-11.4 IV RD(CONV - ATYP); 10.1
per 100 95% CI; 6.6-13.7
CASE-CONTROL STUDIES































Table 2 Studies on the risk of cerebrovascular events associated with antipsychotic medicines










LEVEL I Evidence: Meta-Analyses
Studies that compared atypical antipsychotic (ATYP) treatment to placebo (PLA)
Ballard [1] 1954 dementia patients (age> 60) CV Events Low/High Yes 10-13 weeks % RR (RISP v PLA); 3.64 95% CI; 1.72-7.69
Schneider [6] 5,110 Dementia patients (mean age 81.2) CV Events Low/High Yes 6-26 weeks 0. 1.0% OR (ATYP v PLA); 2.13 95% CI; 1.20-3.75
OR(RISP v PLA); 3.43 95%CI; 1.60-7.32
DeDeyn [4] 1,155 Institutionalised patients (age>=55) CV Events Low/High Yes 12 weeks % Rate in Risperidone group 3.9%
RR not reported
Hermann [32] 1,721 Dementia patients (age>=55) CV Events Low/High Yes 12 weeks % RR (RISP v PLA); 3.2 95% CI; 1.4-7.2
Katz [5] 895 Institutionalised dementia
patients (age>=55)
CV Events Low/High Yes 12 weeks % Rate in Risperidone group 1.6%
RR not reported
DeDeyn [4] 1,155 Institutionalised patients (age>=55) Serious CV Event
requiring hosp.
Low/High Yes 12 weeks % Rate in Risperidone group 1.6%
RR not reported
Hermann [32] 1,721 Dementia patients (age>=55) Serious CV Event
requiring hosp.
Low/High Yes 12 weeks % RR (RISP v PLA); 2.3 95% CI; 0.5-10.7
LEVEL III Evidence: Observational Studies
Studies that compared atypical antipsychotic (ATYP) treatment to non-use (NU)
COHORT STUDIES
Sacchett [33] 74,162 All patients, General Practitioner
Health Search database (Italy) (age>=65)
Diagnosis of stroke
(GPs’ medical records)








RR (ATYP v UNEX); 2.46 95% CI; 1.07-5.65
Barnett [34] 14,029 Dementia patients, Veterans
Affairs Clients (US) (age>=65)
Hospital Admission
for CV event ICD9 435,






18 months % HR (ATYP v NU); 1.20 95% CI; 0.83-1.74
CASE-CONTROL STUDIES
Kolanowski [35] 959 Dementia patients, health care
insured on Southeast US (age>70)




45 days A OR (ATYP v NU); 0.98 95% CI; 0.64-1.52
Liperoti [36] 1130 cases, 3658 controls, institutionalised
dementia patients in six states in the US
(Ohio, Maine, Illinois, Mississippi, South











NR A OR (RISP v NU); 0.87 95% CI;
0.67-1.12 OR (OLA v NU); 1.32
95% CI; 0.83-2.11 OR (Other ATYP
v NU); 1.57 95% CI; 0.65-3.82
SELF-CONTROLLED CASE-SERIES STUDIES
Douglas [37] 6790 All patients with incident diagnosis
of stroke General Practice Research








NR A IRR (ATYP v NU); 2.32 95% CI; 1.73-3.10
Pratt [38] 10638 Australian Department of Veterans
Affairs Veterans/spouses with hospitalization











































Table 2 Studies on the risk of cerebrovascular events associated with antipsychotic medicines (Continued)
Studies that compared conventional antipsychotic (CONV) treatment to non-use (NU)
COHORT STUDIES
Sacchetti [33] 74,162 All patients, General Practitioner
Health Search database (Italy) (age>=65)
Diagnosis of stroke
(GPs’ medical records)






3.5 months 12 per
1000py
RR (BUTY v UNEX); 3.55 95% CI;
1.56-8.07 RR (PHENO v UNEX); 5.79
95% CI; 3.07-10.9
Barnett [34] 14,029 Dementia patients, Veterans
Affairs Clients (US) (age>=65)
Hospital Admission for
CV event ICD9 435,






18 months 3.2% HR (CONV v NU); 1.20 95% CI; 0.48-3.47
CASE-CONTROL STUDIES
Kolanowski [35] 959 Dementia patients, health care
insured on Southeast US (age>70)





45 days NA OR (CONV v NU); 1.18 95% CI; 0.63-2.24
Liperoti [36] 1130 cases, 3658 controls, institutionalised
dementia patients in six states in the US
(Ohio, Maine, Illinois, Mississippi, South
Dakota, New York) (age>85)
Hospital Admission for









NR NA OR (CONV v NU); 1.24 95% CI; 0.95-1.63
SELF-CONTROLLED CASE-SERIES STUDIES
Douglas [37] 6790 All patients with incident diagnosis
of stroke General Practice Research Database








NR NA IRR (CONV v NU); 1.60 95% CI; 1.55-1.84
Pratt [38] 10638 Australian Department of Veterans
Affairs Veterans/spouses with hospitalization







4 years NA IRR (CONV v NU); 1.0 95% CI; 0.8-1.2
Studies that compared all antipsychotics (ANTIP) with no treatment (NU)
COHORT STUDIES
Percudani [39] 1645978 All patients in Lombardy Italy









2 years 2.15 % OR (ANTIP v NU); 1.24 95% CI; 1.16-1.32
Sacchetti [40] 134488 All patients, General Practitioner
Health Search database (Italy) (age>50)
Diagnosis of stroke
(GPs’ medical records)





6 months 3.6 per
1000py
1 month: RR (ANTIP v NU);
12.4 95% CI; 8.4-18.1










1 year NA Current use: OR (ANTIP v NU); 1.6 95%
CI 1.3-2.0 0-7 days: OR (ANTIP v NU);
9.9 (5.7-17.2) 8-14 days :OR (ANTIP
v NU);2.6 (1.3-5.3) 15-30 days: OR
(ANTIP v NU); 2.1 (1.0-4.5) 31-90
days: OR (ANTIP v NU); 1.5 (1.0-2.2)
>90 days: OR (ANTIP v NU); 1.0 (0.7-1.3)
Studies that compared conventional antipsychotic (C) and atypical antipsychotic (A) treatment
COHORT STUDIES








5 years 5.7 per
1000py
RR (RISP v CONV); 1.4 95% CI; 0.7-2.8




















Table 2 Studies on the risk of cerebrovascular events associated with antipsychotic medicines (Continued)
Gill [43] 32710 Dementia patients, administrative









5 years 6.3 % HR(ATYP v CONV); 1.01 95% CI; 0.81-1.26









3 months 0.87 % OR (OLA v RISP); 1.1 95% CI; 0.6-1.7 OR
(QUE v RISP); 0.78 95% CI; 0.2-1.9 OR
(HAL v RISP); 1.9 95% CI; 1.0-3.6
Percudani [39] 1645978 All patients with CV related









2 years 2.37 % OR (ATYP v CONV); 1.42 95% CI; 1.24-1.64
Wang [45] 22890 Patients in Pharmacy













30 days: HR (CONV v ATYP); 1.08 95%
CI; 0.99-1.18 60 days: HR (CONV v ATYP)
1.10 95% CI; 1.02-1.19 180 days: HR
(CONV v ATYP) 1.09 95% CI; 1.02-1.16
IV analyses not reported
Sacchetti [33] 74,162 All patients, General Practitioner
Health Search database (Italy) (age>=65)
Diagnosis of stroke
(GPs’ medical records)






3.5 months 47.4 per
1000py
RR (BUTY v ATYP); 1.44 95% CI;
0.55-3.76 RR (PHENO v ATYP);




















Table 3 Studies on the risk of hip/femur fracture associated with antipsychotic medicines










LEVEL III Evidence: Observational Studies
Studies that compared atypical antipsychotic (ATYP) treatment to non-use (NU)
COHORT STUDIES




NR NR OR (ATYP v NU); 2.2 95% CI; 2.1-2.4
CASE-CONTROL STUDIES











NR NA OR (ATYP v NU); 1.37 95% CI; 1.11-1.69
OR (RISP v NU); 1.42 95% CI; 1.12-1.80
OR (OLA v NU); 1.34 95% CI; 0.87-2.07
OR (OTHERATYP v NU); 1.03 95% CI; 0.47-2.28
Kolanowski [35] 959 Dementia patients, health care







45 days NA OR (ATYP v NU); 1.47 95% CI; 0.82-2.65
Pouwels [48] 6763 cases, 26341 controls All patients,






year of birth, sex,
geographic region)
12 years NA OR (ATYP v NU); 0.83 95% CI; 0.42-1.65
Jalbert [49] 764 cases, 3582 controls Long stay
Medicaid-eligible resident living in nursing










2 years NA New use: OR (ATYP v NU); 1.36 95% CI; 0.95-1.94
Prevalent use: OR (ATYP v NU); 1.33 95% CI; 1.08-1.63
SELF-CONTROLLED CASE SERIES STUDIES
Pratt [50] 8285, Australian Department of Veterans
Affairs Veterans/spouses with hospitalization








4 years NA 1 week: IRR (ATYP V UEXP); 2.17 95% CI;
1.54-3.06 2-8 weeks: IRR (ATYP V UEXP);
1.27 95% CI; 1.04-1.55 9-12 weeks: IRR
(ATYP V UEXP); 1.23 95% CI; 0.92-1.63 >12
weeks: IRR (ATYP V UEXP); 1.43 95% CI; 1.23-1.66
Studies that compared conventional antipsychotic (CONV) treatment to non-use (NU)
CASE-CONTROL STUDIES










NR NA OR (CONV v NU); 1.35 95% CI; 1.06-1.71
OR (HALO v NU); 1.53 95% CI; 1.18-2.26
OR (OTHERCONV v NU); 1.09 95% CI; 0.78-1.52
Kolanowski [35] 959 Dementia patients, health care





45 days NA OR (CONV v NU); 2.33 95% CI; 1.08-5.03
Pouwels [48] 6763 cases, 26341 controls All patients,
PHARMO Database (Netherlands) (age>18)
Hospitalis-ation
for Hip fracture
Moderate Yes (Matched; year
of birth, sex,
geographic region)




















Table 3 Studies on the risk of hip/femur fracture associated with antipsychotic medicines (Continued)
Jalbert [49] 764 cases, 3582 controls Long stay
Medicaid-eligible resident living in nursing
homes with at least 20 beds (age>65)
Hospitalis-ation
for Hip fracture
Moderate Yes (Matched; admitted
to same facility)
2 years NA P valent use: OR (CONV v NU); 1.28 95% CI; 0.7-2.34
SELF-CONTROLLED CASE SERIES STUDIES
Pratt et al. [50] 8285, Australian Department of Veterans
Affairs Veterans/spouses with hospitalization






4 years NA 1 week: IRR (CONV V UEXP); 1.04 95% CI;
0.40-2.70 2-8 weeks: IRR (CONV V UEXP); 2.23
95% CI; 1.65-3.02 9-12 weeks: IRR
(CONV V UEXP); 1.79 95% CI; 1.12-2.84
> weeks: IRR (CONV V UEXP); 2.19 95% CI; 1.62-2.95
Studies that compared all antipsychotics with non-use (NU)
CASE-CONTROL STUDIES
Wang [51] 1222 cases, 4888 controls Elderly patients
enrolled in Medicare as well as in the
New Jersey Medicaid or Pharmaceutical







year birth and gender,
covariate adjustment)
NR NA OR (ATYP v NU); 1.60 95% CI NR
Studies that compared conventional antipsychotic (CONV) and atypical antipsychotic (ATYP) tre ment
COHORT STUDIES




























Table 4 Studies on the risk of pneumonia associated with antipsychotic medicines









LEVEL III Evidence: Observational Studies
Studies that compared atypical antipsychotic (ATYP) treatment to non-use (NU)
CASE-CONTROL STUDIES
Knol [52] 543 cases, 2163 controls All patients;












6 months NR OR (ATYP v NU); 3.1 95% CI; 1.9-5.1
Trifiro [53] 258 cases, 1686 controls Elderly










11 years NA Current use: OR (ATYP v PU); 2.6 95%
CI; 1.5-4.6 Recent use: OR (ATYP v PU);
1.4 95% CI; 0.5-4.1











12 months NA OR (ATYP v NU); 2.3 95% CI; 1.2-4.2
SELF-CONTROLLED CASE SERIES STUDIES
Pratt [50] 13932, Australian Department of
Veterans Affairs Veterans/spouses









4 years NA 1 week:IRR (ATYP V UEXP); 1.73 95%
CI; 1.31-2.29 2-8 weeks: IRR (ATYP V UEXP);
1.70 95% CI; 1.48-1.95 9-12 weeks: IRR
(ATYP V UEXP); 1.67 95% CI; 1.37-2.04
>12 weeks: IRR (ATYP V UEXP);
1.70 95% CI; 1.51-1.93
Studies that compared conventional antipsychotic (CONV) treatment to non-use (NU)
CASE-CONTROL STUDIES
Knol [52] 543 cases, 2163 controls All









Yes (matched) 6 months NA OR (CONV v NU); 1.5 95% CI; 1.2-1.9
Trifiro[53] 258 cases, 1686 controls Elderly








Yes (matched) 11 years NA Current use: OR (CONV v PU); 1.8 95% CI;
1.2-2.5 Recent use: OR (CONV v PU);
1.3 95% CI; 0.8-2.0
SELF-CONTROLLED CASE SERIES STUDIES
Pratt [50] 13932, Australian Department
of Veterans Affairs Veterans/spouses









4 years NA 1 week: IRR (CONV V UEXP); 1.51 95% CI;
1.07, 2.14 2-8 weeks: IRR (CONV V UEXP);
1.62 95% CI; 1.37, 1.92 9-12 weeks: IRR
(CONV V UEXP); 1.69 95% CI; 1.32, 2.16
>12 weeks: IRR (CONV V UEXP); 1.63




















Table 4 Studies on the risk of pneumonia associated with antipsychotic medicines (Continued)
Studies that compared antipsychotic (ANTIP) treatment to non-use (NU)
CASE-CONTROL STUDIES
Knol [52] 543 cases, 2163 controls All patients;










6 months NA 0-8 days: OR (ANTIP v NU); 4.4 95% CI; 2
.9-7.2 8-14 days: OR (ANTIP v NU); 2.3 95%
C 1.1-4.9 15-30 days: OR (ANTIP v NU); 1.9 95%
C 1.0-3.1 31-90 days: OR (ANTIP v NU); 2.0 95%
CI; 1. 3.0 >90 days: OR (ANTIP v NU); 1.1 95% CI; 0.9-0.6
Wada [55] 121, Alzheimers patients in
psychiatric hospital







OR (ANTIP v NU); 3.13 95% CI; 1.46-6.69
Studies that compared conventional antipsychotic (CONV) and atypical antipsychotic (ATYP) tre ment
COHORT STUDIES
Wang [45] 22890 Patients in Pharmacy













180 days NR 30 days: HR (CONV v ATYP); 1.11 95% CI;
76-1.63 60 days: HR (CONV v ATYP); 1.03 95%
I; 0.76-1.38 180 days: HR (CONV v ATYP); 0.84
95% CI; 0.66-1.05 IV analyses not reported
Trifiro [53] 258 cases, 1686 controls Elderly








Yes (matched) 11 years NA Current use: OR (ATYP V CONV); 1.48 95%
CI; 0.84-2.60 Current use: OR (ATY/PHENO v

























Table 5 Efficacy of atypical antipsychotics in elderly patients with dementia: Number needed to treat
Study Study Design Follow-up Risperidone n/N (%) Placebo n/N (%) RD NNT
Clinical End Point
>50% Improvement in Behave-AD1 total score
Katz [62] Double-blind placebo controlled RCT (n=625) 12 weeks (45%) (33%) 12% 8
Schneider [6] Meta Analysis of 3 studies (n=1001) 12 weeks 266/574 (46%) 139/427 (33%) 14% 7.4
>30% Improvement in Behave-AD1 total score
DeDeyn [8] Double-blind placebo controlled RCT (n=344) 12 weeks (72%) (61%) 11% 9
CGI-C2 (much/very much improved)
Brodaty [61] Double-blind placebo controlled RCT (n=93) 12 weeks 27/46 (59%) 12/47 (26%) 33% 3.3
Schneider [6] Meta Analysis of 2 studies (n=717) 8-12 weeks 227/351 (65%) 175/366 (48%) 17% 6
Katz [5] Meta Analysis of 4 studies (n=889) End point (28%) (17%) 11% 9
Sultzer [63] Double-blind placebo controlled RCT (n=421) 12 weeks (61%) (40%) 21% 5
1 BEHAVE-AD: Behaviour Pathology in Alzheimer’s Disease Rating Scale.
2 CGI-C: Clinical Global Impression of Change.
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http://www.biomedcentral.com/1471-2288/12/72increased in the first week only after initiation of anti-
spychotics [38].
A temporal association between antipsychotics and
cerebrovascular events was identified in observational
studies. Three studies, all using different study designs,
found that the risk associated with antipsychotic initi-
ation was highest immediately following treatment initi-
ation but returned to base-line with longer term
treatment [37,40,41].
Observational evidence: studies that compared
conventional and atypical antipsychotic treatment
Six cohort studies compared the risk of stroke between
the classes with conflicting results. Three studies found
equivalent risk between the classes [42-44]. One study
found a reduced risk with conventional compared to
atypical [39] while two found an increased risk [33,45]
with conventional compared to atypical antipsychotics
(Table 2). An instrumental variable analysis found an
increased risk of stroke with conventional antispychotics,
however, the numerical results of this analysis were not
presented [45].
Risk of hip fracture associated with antipsychotic
medicines
Meta-analysis and RCT evidence: studies that compared
antipsychotic treatment to placebo
No RCT evidence for the risk of hip fracture associated
with either conventional or atypical antipsychotics was
located.
Observational evidence: studies that compared
antipsychotic treatment to non-use
Only one observational study employing a cohort design
[46] was located that investigated the association be-
tween antipsychotics and hip fracture. This study founda 2.2 times excess risk of hip fracture with atypical anti-
spychotics compared to non use. Of the four case–con-
trol studies, one found an increased risk of hip fracture
with atypical antipsychotics compared to non-use[47],
two studies found no increased risk [35,48] and one
study found equivalent risk in new users but increased
risk in prevalent users [49]. A self-controlled case-series
study [50] found a significantly increased risk of
hospitalization for hip fracture with atypical antipsycho-
tics which was highest in the first week after initiation.
The risk declined with increased duration of treatment
and remained significantly raised by over 40% with long-
term treatment.
Conventional antipsychotics were associated with a
significantly increased risk of hip fracture in three case–
control studies [35,47,48], while one case–control study
found no increased risk [49]. A self-controlled case-
series study [50] found a significantly increased risk of
hip fracture with conventional antipsychotics after
1 week continuous treatment.Observational evidence: studies that compared atypical and
conventional antipsychotic treatment
Only one cohort study [46] was identified that directly
compared the risk of hip fracture between the classes of
antipsychotics. This study found a significantly increased
risk of hip fracture with conventional antipsychotics
compared to atypical antipsychotics [46] (Table 3).Risk of pneumonia associated with antipsychotic
medicines
Meta-analysis and RCT evidence: studies that compared
antipsychotic treatment to placebo
No RCT evidence for the risk of pneumonia associated
with either atypical or conventional antipsychotics was
located.
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antipsychotic treatment to non-use
Observational evidence for the risk of pneumonia with
atypical antispychotics compared to non-use was limited to
three case–control studies [52-54] and one self controlled
case-series study [50]. The case–control studies found a 2–
3 times increased risk of pneumonia [52-54] (Table 4). A
self controlled case-series study found a 70% increased risk
of pneumonia after initiation of atypical antipsychotics [50].
Two case–control studies found a significantly
increased risk of pneumonia with conventional antipsy-
chotics[52,53] and one self-controlled case-series study
found a 60% increased risk compared to non-exposure.
Two case–control studies of all antipsychotics combined
identified a significantly increased risk of pneumonia asso-
ciated with treatment [52,55]. One study found that the risk
was highest in the first week of treatment and returned to
base-line levels after more than 90 days treatment [52].
Observational evidence: studies that compared atypical and
conventional antipsychotic treatment
Two studies were located comparing the risk of pneu-
monia between the classes [46,54]. Both studies found
no difference in the risk of pneumonia between the
classes [45] (Table 4).
Discussion
This review included 44 studies that evaluated the risk
of either death, cerebrovascular events, hip fracture or
pneumonia associated with antipsychotic prescribing in
the elderly. We found that observational evidence
appears to support the findings from RCTs, where avail-
able, however the magnitude risk differed according to
the methods used to control for confounding.
RCT evidence for atypical antipsychotics showed an
absolute increase of 1 extra death per 100 people trea-
ted. Collectively, observational evidence showed that
conventional antipsychotics were associated with a
greater risk of death than the atypical antipsychotics,
however, the estimates of absolute risk differed between
studies. Risk estimates from covariate adjusted cohort
studies ranged from 2 to 3 extra deaths per 100 patients
treated with conventional compared to atypical antipsy-
chotics over 6 months while instrumental variable ana-
lysis estimates ranged from 4 and 7 extra deaths per 100
patients over 6 months. These discrepancies suggest that
unmeasured confounding may have contributed to an
underestimate of risk in the traditional cohort studies.
Many of the cohort studies also employed propensity
score methods to adjust for confounding either by use of
propensity score matching [22,26] or numerical adjust-
ment by propensity score quintiles [28,29,31]. In these
latter studies propensity score adjustment estimates were
consistent with multivariate adjusted results whileinstrumental variable analyses were marginally different
suggesting some residual unmeasured confounding in
the propensity score and multivariate adjusted analyses.
Additionally studies have undertaken sensitivity analyses
to rule out potential bias from unmeasured confounding
which revealed that only very strong unmeasured con-
founders would explain the observed increased mortality
association with conventional antipsychotic use, if in
fact, the observed difference was not true [22,28].
RCT evidence of the risk of cerebrovascular events
was limited to the atypical antipsychotics and demon-
strated an increased risk of all cerebrovascular events[1]
but not serious strokes requiring hospitalization [4,33].
Cerebrovascular events were the most studied and
reported adverse event in observational studies of anti-
psychotics compared to non-use, however, the definition
of this outcome was not consistent between studies. In
general, cohort studies reported negative associations
when investigating cerebrovascular hospitalisation events
and positive associations when investigating outcomes
defined as a diagnosis of all cerebrovascular events from
general practitioners’ medical records which supports
the findings from available RCTs. In contrast, case–
control studies failed to find statistically significant results
for either outcome definition. Case–control studies often
employ techniques to minimise possible bias, such as
matching or numerical adjustment for potential con-
founders, however, studies of this type may still be sub-
ject to unmeasured confounding [57]. Self-controlled
case-series studies found similar results to RCT evidence
when similar definition of cerebrovascular events were
used which suggests that this technique may be a reli-
able design for the investigation of adverse events not
previously detected in RCTs. One of the advantages of
the self-controlled case-series design is that it controls
implicitly for patient-specific confounders that do not
vary over time. This means that it is not necessary to ad-
just for variables such as sex, frailty or other risk factors
that are constant over time. However, a limitation of this
approach is that it is unable to adjust for changes in pre-
scribing due to rapid changes in underlying disease sever-
ity [17]. Observational cohort studies comparing the
antipsychotic classes have used consistent definitions of
outcome, specifically, hospitalisation for stroke, however,
results vary according to the methods employed to adjust
for differences between treatment groups. Of the 6 studies
that used numerical covariate adjustment, three found no
difference in risk [42-44] between the classes, one found a
reduced risk [39], while two found an increased risk
[33,45] with conventional compared to atypical antispy-
chotics. One study [45], used an instrumental variable
method to adjust for unmeasured confounding. This study
found a 10% increased risk of stroke with conventional
compared to atypical antipsychotics but only after 60 days
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were not presented and the prevalence of cerebrovascular
disease at baseline in the studied population, described in
a separate paper, was high [29].
While no RCT data for the risk of hospitalisation for hip
fracture could be located, a Cochrane review [1] found
that risperidone may be associated with an increased risk
of falls in the elderly which suggests that an increased risk
of hip fracture may also be likely. Observational studies
reported an increased risk of hip fracture with both classes
compared to non-use and this risk may increase with in-
creasing duration of therapy. A study using a self-
controlled case-series design [50], found an increased risk
of hospitalization for hip fracture for both conventional
and atypical antipsychotics. It is unclear whether the risk
of hip fracture differs between the classes. Only one co-
hort study [46] investigated the comparative risk of hip
fracture between the classes finding an increased risk with
conventional antipsychotics.
Meta-analyses [19-50,52-58] of randomized controlled
trials found that one of the major causes of death asso-
ciated with atypical antipsychotics was pneumonia. Few
observational studies, however, have investigated the
risk of pneumonia associated with antipsychotics in eld-
erly patients, and most have used a case–control design.
An increased risk of pneumonia was found with both
classes [52,55] compared to non-use or previous use
[53]. One case–control study identified that the risk
appeared to be highest in the first week of treatment
but returned to baseline after 90 days [52]. A study
using a self-controlled case-series design [50] also found
and increased risk of hospitalization for pneumonia for
both conventional and atypical antipsychotics. The risk
of pneumonia was similar between the classes [46,54].
One study, which used an instrumental variable ana-
lysis, found no difference in the risk of pneumonia be-
tween conventional and atypical antipsychotics [45].
As in any systematic review, publication bias is a potential
limitation of this study. It is possible that only positive ob-
servational study findings may have been published. In par-
ticular, the majority of published studies investigating hip
fracture and pneumonia associated with antipsychotics
reported significantly increased risks with treatment com-
pared to non-use. Additionally, our search criteria specified
that only those study designs that resulted in standard ef-
fect estimates were included for comparison purposes. We
therefore excluded case reports and studies that used
designs such as the self-controlled cohort analysis [59]. We
only included outcomes that could be consistently defined
to limit heterogeneity across studies. The endpoints for this
study, cerebrovascular events, hip fracture and pneumonia,
were chosen because we believed that patients were likely
to present to hospital for these conditions, and therefore
were outcomes that would most likely be available inobservational studies using administrative claims databases.
The application of methods such as the self controlled
case-series and instrumental variable analyses have evolved
mainly to address unmeasured confounding due to the lack
of clinical information in claims databases. Antipsychotics
have also been associated with other adverse events such as
deep vein thrombosis, diabetes onset and heat stroke which
were not included in this review.
The aim of this review was to explore the effects of
study design on the results of observational studies of
antipsychotics. To do this we simplified our comparisons
to with-in class comparisons and we have not considered
differences according to individual products, dose or ef-
fect modifiers. The majority of published observational
studies have provided comparisons between classes,
however, where available we have presented the results
by individual products and by dose. Besides study design,
many other factors may have contributed to the differ-
ences observed among observational studies. These in-
clude differences in populations studied, in terms of
drug utilization patterns and health care settings, differ-
ences in the definition of outcome and variations in the
number and type of confounders that may have been
included in the analysis. We have attempted to limit the
impact of these effects by considering the effects of anti-
psychotics in the elderly only and by limiting our events
to serious adverse events potentially requiring
hospitalization. In the case of cerebrovascular events we
considered cerebrovascular events separately to hospita-
lizations for stroke as these were the two events most
often considered in observational studies.
Where possible we compared available meta-analyses
and randomised controlled trial evidence with the results
of observational studies, however, experimental evidence
was typically generated prior to when many of the obser-
vational studies were performed and may have included
different patient populations. RCT evidence is generally
considered of higher quality than observational studies,
[18] however, there are many examples where RCTs on
the same clinical topic have produced conflicting results
[60]. High quality observational studies, whether cohort
or case–control designs, have consistently found similar
results to RCTs [60].
Conclusions
This review has identified that the harms associated with
antipsychotics in the elderly are under reported in pub-
lished RCTs and the risks of treatment may not be limited
to death and cerebrovascular events. Collectively, evidence
suggests that atypical antipsychotics are associated with
an increased risk of death, cerebrovascular events, hip
fracture and pneumonia. Based on RCT evidence
[5,6,8,61-63] the number needed to treat with risperidone
to show clinical benefit ranges from 3 to 9 patients over a
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patients treated with risperidone we would expect be-
tween 8 and 33 patients to receive any clinical improve-
ment in symptoms of aggression or psychosis. The
risk-benefit ratio suggests that there will be 1 excess death
for every 11 to 33 person helped with these medicines
[19], 1 excess hospitalization for hip fracture for every 4 to
12 patients helped and 1 excess hospitalization for pneu-
monia for every 2 to 5 patients helped [50]. Considering
the modest improvement in terms of efficacy and the
increased risk of mortality associated with hip fracture
and pneumonia, the risks associated with antipsychotics
may now outweigh their benefit. In the absence of RCT
data, good quality observational studies will be required,
that employ appropriate study designs that are robust to-
wards unmeasured confounding, to clarify the risks of
antipsychotic use in the elderly.
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